• Tetrandrine: Research Context and Evidence Limits

  2026-10-09

  Tetrandrine is a natural-product research compound associated with calcium-channel and signaling studies. This overview separates catalog information from peer-reviewed evidence, examines conceptual applications in ion channel modulation, neuroscience, inflammation, and cancer biology, and explains why a 2021 computational SARS-CoV-2 NSP15 study does not establish tetrandrine as an antiviral lead.

• EGCG Research Context, Findings, and Limitations

  2026-10-08

  (-)-Epigallocatechin gallate (EGCG) is a green tea catechin studied in infection, cancer, antiviral, and cell-signaling research. This overview examines the 2024 in vitro evidence for EGCG analogs against Staphylococcus aureus, compares it with broader product-level claims, and defines the main translational limitations.

• Obeticholic Acid in FXR and Liver Fibrosis Research

  2026-10-08

  Obeticholic Acid is a selective FXR agonist used to investigate bile acid regulation, cholestasis, inflammation, and fibrosis. This overview separates supplier-reported pharmacology from published evidence and compares FXR-centered research with findings from a 2025 study of 11β-HSD1 inhibition in mouse liver fibrosis.

• Procainamide Hydrochloride: Research Context

  2026-10-07

  Procainamide Hydrochloride is best understood as a compound with established cardiac electrophysiology relevance and additional, less mature research claims involving epigenetic and immunomodulatory biology. The supplied pregnancy-mouse study provides focused evidence about its use alongside cisplatin, but its findings do not establish clinical safety, general chemoprotection, or efficacy in humans.

• Sumatriptan Succinate: From Receptor to Translation

  2026-10-07

  A mechanism-led view of Sumatriptan Succinate as a translational research tool, connecting 5-HT1B/1D pharmacology, neurovascular signaling, inflammation hypotheses, and evidence from a pediatric emergency department study.

• Diclofenac and Human Intestinal Organoid Evidence

  2026-10-06

  Diclofenac is a non-selective COX inhibitor with established relevance to inflammation and pain signaling research. This evidence-focused review examines how human iPSC-derived intestinal organoids can clarify cyclooxygenase biology and pharmacokinetic interpretation without overstating what the current literature demonstrates.

• KR-12 Human Antimicrobial Peptide: Evidence Guide

  2026-10-06

  KR-12 is a compact human antimicrobial peptide fragment derived from LL-37. Evidence supports membrane-targeting, anti-biofilm, LPS-neutralizing, and immunoregulatory research relevance, but reported assay conditions and translational boundaries limit direct comparison across studies.

• SB 225002: Evidence, Scope, and CXCR2 Interpretation

  2026-10-05

  A source-grounded overview of what SB 225002 can and cannot show in CXCR2, IL-8, neutrophil chemotaxis, inflammation, and cancer research, with particular attention to a 2026 study linking MRSA extracellular vesicles to CXCR1-centered signaling in oral cancer.

• Phenacetin in Human-Relevant PK Models

  2026-10-05

  Phenacetin can serve as a historically informative, research-only small-molecule comparator for evaluating human-relevant intestinal pharmacokinetic models. This article connects the compound’s uncertain mechanism and nephropathy history with new findings on hiPSC-derived intestinal organoids, while distinguishing platform capability from phenacetin-specific evidence.

• Dimethyloxalylglycine (DMOG) Overview

  2026-10-04

  Dimethyloxalylglycine (DMOG), SKU A4506, is an APExBIO research chemical described as a cell-permeable competitive PHD inhibitor for conceptual studies of HIF regulation and hypoxia signaling. No matched paper evidence was supplied, so performance, mechanisms, and applicability remain unverified here.

• (S)-(+)-Ibuprofen: Five Evidence Questions

  2026-10-03

  A source-grounded overview of (S)-(+)-Ibuprofen as a COX inhibitor, covering its pharmacological principle, environmental evidence, interpretation, research scope, and key limitations.

• Rimonabant (SR141716): A CB1 Assay Compass

  2026-10-02

  Rimonabant (SR141716) is more than a CB1 antagonist for appetite studies: it is a causal pharmacology tool for separating receptor-dependent withdrawal, locomotor, and sex-related effects. This article translates recent rat findings into practical assay-design decisions for obesity research, neurobiology, and endocannabinoid signaling.

• DZNep: EZH2 and Chromatin-State Workflows

  2026-10-01

  DZNep provides a practical way to perturb EZH2-associated repression, H3K27me3, proliferation, and apoptosis across AML and metabolic inflammation models. This guide separates evidence-backed use cases from exploratory hPSC experiments and shows how to build reliable dosing, chromatin, and phenotype readouts.

• Baicalein Workflows for Cancer and Inflammation

  2026-10-01

  Baicalein enables controlled studies of 12-lipoxygenase, apoptosis, cancer cell proliferation, and inflammatory signaling when biochemical and cellular assays are aligned. This practical workflow emphasizes solvent control, orthogonal readouts, and a careful translation of neuroprotection findings into cancer and inflammation research.

• Isochlorogenic Acid A: Translational Wound Repair

  2026-09-30

  Isochlorogenic acid A, also known as 3,5-Dicaffeoylquinic acid, is moving from natural product research into engineered wound-repair systems. This thought-leadership analysis examines the formulation logic, preclinical evidence, experimental controls, and translational questions surrounding its use in multifunctional hydrogels.

7875 records 1/525 page Next 12345 下5页 Last page